Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.55 |
| ▸ | CTSS | P25774 | 6/20 | 0.47 |
| ▸ | CTSK | P43235 | 5/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17931623 | 0.91 | MAOB (0.52) | MAOBCTSSCTSKESR1ESR2 | |
| SCHEMBL17935575 | 0.85 | MAOB (0.57) | MAOBACACB | |
| SCHEMBL16552370 | 0.83 | MAOB (0.77) | MAOB | |
| SCHEMBL17923788 | 0.82 | MAOB (0.72) | MAOBESR1ESR2OPRK1CTSL | |
| SCHEMBL17923791 | 0.82 | MAOB (0.72) | MAOBESR1ESR2OPRK1CTSL | |
| SCHEMBL28291236 | 0.82 | MAOB (0.72) | MAOBESR1ESR2OPRK1CTSL | |
| SCHEMBL16552343 | 0.80 | MAOB (0.48) | MAOBCTSSCTSKACACB | |
| SCHEMBL17931620 | 0.75 | ACACB (0.37) | MAOBOPRK1ACACBOPRM1OPRD1 | |
| SCHEMBL17931622 | 0.74 | ACACB (0.36) | MAOBOPRK1ACACBOPRM1OPRD1 | |
| SCHEMBL17931628 | 0.73 | ACACB (0.36) | MAOBOPRK1ACACBOPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160207878-A1 | MAO-B Selective Inhibitor Compounds, Pharmaceutical Compositions Thereof and Uses Thereof | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2016-07-21 | — | — | US | disclosed |
| US-20160207878-A1 | MAO-B Selective Inhibitor Compounds, Pharmaceutical Compositions Thereof and Uses Thereof | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2016-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207878-A1 | MAO-B Selective Inhibitor Compounds, Pharmaceutical Compositions Thereof and Uses Thereof | MAOB, MAOA, COMT | MAOB 1/4885CTSS 179/4885CTSK 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.